is a key enzyme that catalyzes the hydrolysis of DHEAS to the biologically active DHEA. DHEA is further metabolized to the active androgens that bind the androgen receptor (AR) leading to cell proliferation. STS plays important roles in hormone-responsive malignant growth including prostate cancer. The aim of this study is to determine the role of STS in AR signaling and to explore the potential of targeting STS overcoming castration resistance in prostate cancer.
INTRODUCTION AND OBJECTIVES: Steroid sulfatase (STS)
is a key enzyme that catalyzes the hydrolysis of DHEAS to the biologically active DHEA. DHEA is further metabolized to the active androgens that bind the androgen receptor (AR) leading to cell proliferation. STS plays important roles in hormone-responsive malignant growth including prostate cancer. The aim of this study is to determine the role of STS in AR signaling and to explore the potential of targeting STS overcoming castration resistance in prostate cancer.
METHODS: Sensitivity of prostate cancer cells to STS inhibitors was tested using cell growth assays and clonogenic assays. Quantitative reverse transcription-PCR, and Western blotting were performed to detect expression levels of STS and AR. Expression of STS was downregulated using siRNA specific to STS. Stable cell lines overexpression of STS were generated and characterized. Steroid profile including DHEA and androgens was analyzed by Liquid Chromatography-Mass Spectrometry (LC-MS). STS activity was determined by 4-Methylumbelliferyl sulfate assay through a fluorescence microtiter plate reader. PSA secretion was determined by ELISA and PSA-luciferase activity was measured by reporter assay. Eleven potent STS inhibitors were synthesized and characterized. Two novel STS inhibitors in vivo efficacy was tested in castration relapsed VCaP xenograft tumor models.
RESULTS: We found STS is overexpressed in CRPC patients and cells. Overexpression of STS in the STS stable expression cells promotes the cellular growth of both LNCaP and C4-2B cells in vitro. Inhibiting STS by siRNA suppresses cell growth and AR signaling. Selected from 11 potential STS inhibitors, two novel small molecule inhibitors (SI-1 and SI-2) inhibit the STS activity and the growth of C4-2B and VCaP cells. SI-1 and SI-2 also significantly suppressed AR transcriptional activity, suggesting that inhibition of STS activity by STS inhibitors downregulates the AR signaling. Additionally, SI-1 and SI-2 significantly suppressed the growth of relapsed VCaP cells and tumors and improved enzalutamide treatment in vitro and in vivo.
CONCLUSIONS: STS is involved in castration resistance prostate cancer and inhibition of this enzyme could be a viable strategy to treat CRPC and improve enzalutamide treatment.
Source of Funding: NIH CA179970

MP68-16 XENOBIOTIC METABOLISM OF ABIRATERONE ACETATE AND GLUCOCORTICOIDS BY THE GUT MICROBIOTA
Kamilah Abdur-Rashid*, Shiva Nair, Ryan Chanyi, Joseph Chin, Jeremy Burton, London, Canada INTRODUCTION AND OBJECTIVES: Testosterone and dihydrotestosterone (DHT) stimulate the growth of prostate cancer by activating androgen receptors. Androgen deprivation therapy (ADT), the first line of systemic treatment, aims to decrease circulating androgens to castrate levels; however, castration resistant prostate cancer (CRPC) can develop. Abiraterone acetate (AA), an inhibitor of androgen synthesis, in combination with supportive glucocorticoids are used to treat CRPC. Many drugs are orally ingested and pass through the gastrointestinal tract, however, the dense bacterial population in the gut is often overlooked. We hypothesize that AA can modify the composition of the gut microbiota and gut bacteria can transform glucocorticoids into compounds that can activate androgen receptors.
METHODS: A chemostat gut model was inoculated with human feces and exposed to physiological doses of AA. Samples were analyzed by culture-dependent and -independent methodologies. Bacterial isolates that increased in abundance upon exposure to AA were tested on agar containing AA. Secondly, Clostridium scindens, a corticosteroid-utilizing gut bacterium with known androgenic-producing abilities, were exposed to various clinically relevant glucocorticoids (prednisone, prednisolone and dexamethasone). The metabolic products were measured by liquid chromatography-mass spectrometry and bacterial gene expression by quantitative PCR. A yeast-based human androgen receptor assay was also used to detect the biotransformation of glucocorticoids for potential activation by bacterial metabolites.
RESULTS: The bacterial composition of the gut model changed when exposed to AA. Select bacterial isolates were also able to utilize AA as a sole carbon source. C. scindens was found to metabolize prednisone, prednisolone and dexamethasone, possibly using machinery encoded on the desABCD operon. Gene expression analysis revealed increased expression of: desA by 8-fold; desB by 5.2-fold; desC by 4.8-fold; and desD by 2.6-fold. DHT-like activity on human androgen receptor assay increased significantly with C. scindens incubation with prednisone (3.6AE0.8Â10 À9 M) but not with prednisolone (no detectable activation) or dexamethasone (no detectable activation).
CONCLUSIONS: These results suggest that we may need to consider the role of the gut microbiota in the treatment of CRPC. Bacterial interactions may change the pharmaceutical properties of drugs such as AA. Prednisone, co-administered with AA, can also be metabolized into androgenic compounds, which may play a part in CRPC treatment failure.
Source of Funding: none
MP68-17 ENZALUTAMIDE-INDUCED ANTIANDROGEN-RESISTANCE VIA A UNIQUE TRANS-SPLICING MECHANISM TO INDUCE A NOVEL ANDROGEN RECEPTOR MUTANT ARV33
Ronghao Wang*, Chawnshang Chang, Shuyuan Yeh, Rochester, NY INTRODUCTION AND OBJECTIVES: Prostate cancer (PCa) is the second leading cause of cancer-related death among men in western countries. Therefore, dissection of the underlying mechanisms and developing the new drugs to fight against PCa have important implications. It is widely accepted that androgen receptor (AR) signaling plays crucial role in the initiation and progression of PCa.A more powerful anti-androgen enzalutamide (Enz, also called MDV3100) was recently approved to treat castration-resistant prostate cancer (CRPC) that can extend PCa patients survival by 4.8 months. Nevertheless, Enz resistance caused by multiple mechanisms limits its further application.
METHODS: Enz resistance cell line was established by long term exposure of Enz. Taqman probe and specific antibody were used to confirm AR variant.
RESULTS: we uncovered a new AR variant (named as ARv33 due to its duplicated exon3) was dramatically induced in our established Enz-resistant PCa cells based on divergent PCR analysis. Sequence analysis using two-round PCR revealed that this AR variant has intact AR's exons but with additional exon3. This AR variant could interact with AR-v7 to render enzalutamide resistance to PCa and deficiency of its expression could restore Enz sensitivity in EnzR cells. Importantly, our preliminary data also demonstrated that the induction of this new AR-v33 variant is not due to genomic alteration, and probably, it may be generated from a trans-splicing event of pre-AR transcript.
CONCLUSIONS: This newly identified ARv33 may play key roles to alter the Enz resistance, and targeting this ARv33 may provide us a new and better therapy to further suppress the CRPC cells that already developed the Enz resistance. Vol. 201, No. 4S, Supplement, Sunday, May 5, 2019 THE JOURNAL OF UROLOGY Ò e981
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